Phase II, single-arm study (PHAROS) Treatment-naïve and previously treated with BRAFV600E-mutant metastatic NSCLC Encorafenib +Bininmetinib q28 (n=98)

24 Jun

GastroEsophageal Cancer

New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer

Open-label, multicenter, phase Ib/II trial HER2-positive advanced G/GEJ cancer that progressed from trastuzumab-containing first-line chemotherapy with fluoropyrimidine and platin

24 Jun

Hodgkin Lymphoma

New Protool: Nivolumab-AVD in Hodgkin Lymphoma

Phase III, randomized, controlled study (SWOG S1826) Previously untreated pts were ≥12 years (y) with stage 3-4 HL N-AVD (n=489) vs. BV-AVD (n=487)

20 May

Breast Cancer

New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer

Phase III, randomized, open-label trial (monarchE) Hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence Abemaciclib + ET (n=280

16 Mar

Nervous System Tumor

New Indication: Dabrafenib and Trametinib in bRAF V600E Mutant Glioma

Open-label, single-arm, phase 2, basket trial BRAFV600E mutation-positive high- low-grade glioma Prior radiotherapy and chemotherapy or chemoradiotherapy for high grade glioma Dabr

24 Jun

Hepatocellular Carcinoma

New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC

Phase III, randomized, controlled, multicenter, open-label trial (İMbrave050) HCC pts at high risk of recurrence following resection or ablation. Atezolizumab + Bevacizumab q21 (n

15 Mar

Mantle cell lymphoma

New Drug: Pirtobrutinib in Mantle Cell Lymphoma

Open-label, multicenter, single-arm trial (BRUIN) Mantle cell lymphoma previously treated with a BTK inhibitor Pirtobrutinib (n=120)

20 Aug

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab in Large B-Cell Lymphoma

Phase I-II, open-label, multicenter study Relapse or refractory large cell lymphoma Glofitamab (n=132)

20 May

Skin Cancer (Other than Melanoma)

New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

Open-label, multicenter, single-arm, phase 2 study Treatment naïve metastatic or recurrent locally advanced MCC Retifanlimab q28 (n=65)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries